{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:02Z","timestamp":1790057042125,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.06.021","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T16:32:23Z","timestamp":1561221143000},"page":"4243-4245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch"],"prefix":"10.1016","volume":"37","author":[{"given":"G.","family":"Deceuninck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Betala-Belinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Serres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De Wals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.06.021_b0005","doi-asserted-by":"crossref","unstructured":"Law DKS, Lorange M, Ringuette L, Dion R, Gigu\u00e8re M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 Serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol. 2006;44:2743\u20139.","DOI":"10.1128\/JCM.00601-06"},{"key":"10.1016\/j.vaccine.2019.06.021_b0010","doi-asserted-by":"crossref","first-page":"e50659","DOI":"10.1371\/journal.pone.0050659","article-title":"The changing epidemiology of meningococcal disease in Quebec, Canada, 1991\u20132011: potential implications of emergence of new strains","volume":"7","author":"Gilca","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.06.021_b0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of Serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.021_b0020","unstructured":"De Wals P, Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, DeSerres G. Impact \u00e9pid\u00e9miologique de la campagne de vaccination contre le m\u00e9ningocoque de s\u00e9rogroupe B dans la r\u00e9gion du Saguenay-Lac-Saint-Jean en 2014: rapport au 30 juin 2018. Quebec City (QC): Institut national de sant\u00e9 publique du Qu\u00e9bec; 2018. Available from: <https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/2491_impact_vaccination_meningocoque_serogroupe_b.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.021_b0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.021_b0030","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.06.021_b0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.021_b0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.021_b0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000002334","article-title":"Immunogenicity and safety of a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 6 years after MenC priming as toddlers","volume":"38","author":"Nolan","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.021_b0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.021_b0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/21645515.2017.1394535","article-title":"Improving vaccine coverage in adolescence and beyond","volume":"14","author":"Falconer","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.06.021_b0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.06.021_b0065","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1016\/j.vaccine.2018.10.095","article-title":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada","volume":"36","author":"De Serres","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:12Z","timestamp":1759401192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":13,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19307820"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}